ストックスクリーナーアプリを入手
10.78
5.69%
-0.65
アフターアワーズ：
10.82
0.04
+0.37%
Biohaven Ltd (BHVN) 最新ニュース
Ono Pharmaceutical (TSE:4528) Secures Biohaven Asia Rights, Is The Stock Still A Bargain? - Simply Wall Street
Ono extends I&I reach in $100M Biohaven deal for IgG degraders - BioWorld News
Biohaven partners with Ono in $100m IgG degrader deal - Pharmaceutical Technology
Biohaven Licenses IgG Degrader Portfolio to Ono for $80 Million Upfront - BigGo Finance
Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement - Benzinga
Biohaven licenses IgG degrader portfolio to Ono for USD 80 million upfront - AllSci
Biohaven signs licensing deal with Japanese drugmaker worth up to $100M - Hartford Business Journal
Biohaven licenses IgG degrader portfolio to Japan’s Ono (BHVN:NYSE) - Seeking Alpha
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease - PR Newswire
Is Biohaven (BHVN) Quietly Recasting Its Oncology Strategy Through Deeper Ties With Regeneron? - Yahoo Finance
Bexorg Awarded Up to $28.3 Million from ARPA-H to Advance Human Brain Translational Pharmacology for CNS Drug Development - GlobeNewswire Inc.
Roche’s AI lab; Biohaven’s pivotal pause - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), AxoGen (AXGN) and Biohaven Ltd. (BHVN) - The Globe and Mail
Biohaven Ltd. (BHVN) stock price, news, quote and history - Yahoo Finance Singapore
Biohaven’s cancer drug data selected for presentation at symposium - Investing.com
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 - PR Newswire
Has Biohaven (BHVN) Fallen Far Enough to Look Fully Priced? - Yahoo Finance
Yale, Biohaven Seek $23M Atty Fee After Trade Secrets Win - Law360
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 49.55% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Biohaven (BHVN) Gains Attention As Pipeline Hopes Meet A Big Fair Value Gap - simplywall.st
Biohaven (NYSE:BHVN)Stock Analysis - Simply Wall Street
BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout - Stocktwits
Biohaven (BHVN) discloses options tied to SVP's son - Stock Titan
Biohaven (BHVN) Could Be 82% Undervalued Following FDA Hold On Opakalim Trials - simplywall.st
Biohaven Faces New Securities Investigation - stl.news
Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN) - PR Newswire
Why Is Biohaven (NYSE:BHVN) Opakalim Under FDA Hold on NYSE Composite? - Kalkine Media
What Does Biohaven (BHVN) FDA Hold Mean For Its Opakalim Program? - simplywall.st
What Does Biohaven (BHVN) FDA Hold Mean For Its Opakalim Program? - simplywall.st
Biohaven’s epilepsy drug hit with FDA clinical hold - Yahoo Finance
Biohaven pauses new enrollment in epilepsy trials after FDA partial clinical hold By Investing.com - Investing.com South Africa
Biohaven’s Newly Out-Licensed Epilepsy Drug Put On A Partial Clinical Hold - insights.citeline.com
Biohaven: The Hold Isn't The Problem (Rating Downgrade) (NYSE:BHVN) - Seeking Alpha
Biohaven Shares Plunge as FDA Halts New Enrollment in Epilepsy Drug Trials - finance.biggo.com
BHVN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10 - GuruFocus
FDA pauses enrollment in Biohaven’s opakalim trials; pivotal readout remains on track - AllSci
Why is Biohaven Pharmaceutical stock sliding today? - investing.com
Baird reiterates Biohaven stock rating after regulatory update By Investing.com - Investing.com Nigeria
BHVN Stock Slips As Kv7 Deal Seen As Stopgap Move - StocksToTrade
BHVN Stock Slips As SK Deal Seen As Buying Time - timothysykes.com
Baird reiterates Biohaven stock rating after regulatory update By Investing.com - Investing.com South Africa
Baird reiterates Biohaven stock rating after regulatory update - Investing.com
Baird reiterates Biohaven stock rating after regulatory update By Investing.com - Investing.com Canada
Baird reiterates Biohaven stock rating after regulatory update By Investing.com - Investing.com India
Why Is Biohaven Stock Tumbling Today?Biohaven (NYSE:BHVN) - Benzinga
FDA Places Partial Clinical Hold on Biohaven’s BHV-7000 Epilepsy Enrollment - Minichart
Biohaven Shares Fall 17% After FDA Places Partial Hold on BHV-7000 Trials - Yahoo Finance
BHVN Stock Crashes 10% – Why Did FDA Put Biohaven’s Epilepsy Trial On Partial Hold? - Yahoo Finance
FDA places partial hold on Biohaven’s epilepsy drug - Yahoo Finance
Form 8K Biohaven Pharmaceutical Holding Co For: 10 September By Investing.com - Investing.com Nigeria
2.20%
0.71%
大文字化:
|
ボリューム (24 時間):